Dinapsoline

Dinapsoline is een medicijn ontwikkeld voor de behandeling van de ziekte van Parkinson,^[1] dat fungeert als een selectieve volledige agonist op de dopamine D -₁ receptor.^[2]^[3]^[4]^[5]

Bronnen, noten en/of referenties

↑ (February 2001)Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics 296 (2): 338–44 . PMID: 11160615.
↑ (January 1996)9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. Journal of Medicinal Chemistry 39 (2): 549–55 . PMID: 8558526. DOI: 10.1021/jm950707+.
↑ (August 2002)(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist. Journal of Medicinal Chemistry 45 (17): 3660–8 . PMID: 12166939. DOI: 10.1021/jm0101545.
↑ (February 2004)Synthesis and SAR exploration of dinapsoline analogues. Bioorg. Med. Chem. 12 (4): 715–34 . PMID: 14759732. DOI: 10.1016/j.bmc.2003.11.015.
↑ (May 2006)Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine. Psychopharmacology 186 (1): 25–31 . PMID: 16575553. DOI: 10.1007/s00213-006-0342-2.